Another critical emphasis was to know whether bispecific targeting of liposomes with HER2’scFv together with FAP specific scFv would influence HER2’scFv based binding, and if the liposomes would deliver cargos into the nuclei of tumor cells in vivo similar to trastuzumab-targeting liposomes. The gene discussed is FAP; the disease is neoplasm.